A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Public ClinicalTrials.gov record NCT06846671. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
Study identification
- NCT ID
- NCT06846671
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Interventions
- Tacabrutideg Drug
- Bendamustine Drug
- Idelalisib Drug
- Rituximab Drug
- Venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 9, 2025
- Primary completion
- May 14, 2028
- Completion
- Feb 13, 2030
- Last update posted
- Aug 23, 2026
2025 – 2030
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St Bernards Medical Center | Jonesboro | Arkansas | 72401 | Recruiting |
| UCLA Department of Medicine Hematologyoncology | Los Angeles | California | 90095-3075 | Recruiting |
| Pih Health Whittier Hospital | Whittier | California | 90602 | Recruiting |
| Rocky Mountain Cancer Centers (Williams) Usor | Aurora | Colorado | 80012-5405 | Recruiting |
| Florida Oncology and Hematology | Fort Myers | Florida | 33912 | Recruiting |
| Baptist Md Anderson Cancer Center | Jacksonville | Florida | 32207-8432 | Recruiting |
| Cleveland Clinic Florida | Weston | Florida | 33331-3609 | Recruiting |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322-1013 | Recruiting |
| Northside Cancer Center | Atlanta | Georgia | 30342 | Recruiting |
| Our Lady of the Lake Hospital | Baton Rouge | Louisiana | 70808-4365 | Recruiting |
| American Oncology Partners of Maryland Pa | Bethesda | Maryland | 20817-7847 | Recruiting |
| Corewell Health the Michigan Cancer Consortium | Grand Rapids | Michigan | 49503-2560 | Recruiting |
| St Lukes Center For Cancer Care | Chesterfield | Missouri | 63017 | Recruiting |
| Oncology Hematology Associates | Springfield | Missouri | 65807-5288 | Recruiting |
| St Vincent Frontier Cancer Center | Billings | Montana | 59102-6746 | Recruiting |
| Oncology Hematology West, Pc Dba Nebraska Cancer Specialists | Omaha | Nebraska | 68130-2042 | Recruiting |
| Memorial Sloan Kettering Cancer Center Mskcc | New York | New York | 10065-6800 | Recruiting |
| New York Cancer and Blood Specialists | Shirley | New York | 11967 | Recruiting |
| Optum Medical Care, Pc | Westbury | New York | 11590-5119 | Recruiting |
| University Hospitals | Cleveland | Ohio | 44106-1716 | Recruiting |
| Dayton Physician Network | Dayton | Ohio | 45415 | Recruiting |
| Oncology Associates of Oregon Willamette Valley Cancer Center | Eugene | Oregon | 97401 | Recruiting |
| West Penn Hospital | Pittsburgh | Pennsylvania | 15224 | Recruiting |
| Cancer Care Associates of York | York | Pennsylvania | 17403-5049 | Recruiting |
| Baylor Scott and White Health | Temple | Texas | 76508-0001 | Recruiting |
| Texas Oncology Tyler | Tyler | Texas | 75702-7522 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06846671, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2026 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06846671 live on ClinicalTrials.gov.